The once-daily oral drug has been cleared under the Veozah brand name for moderate to severe vasomotor symptoms (commonly known as hot flashes) in menopausal women, becoming a non-hormonal ...

The oral neurokinin (NK) 1 and 3 antagonist – if approved – will represent the first direct competition to Astellas' NK 3 antagonist Veozah (fezolinetant) which was cleared by the FDA in May ...

And there are innovations outside of hormone therapy, such as a nonhormonal medication called Veozah (fezolinetant), used ...